Tag Archives | PMI

Defeating malaria through pharmaceutical systems strengthening

SIAPS has received funding from the US President’s Malaria Initiative (PMI) to work in eight countries—Angola, Burundi, Democratic Republic of the Congo (DRC), Ethiopia, Kenya, Guinea, Mali, and South Sudan—to strengthen pharmaceutical systems for improved malaria control. This report synthesizes the pharmaceutical systems strengthening efforts of SIAPS and documents how the approach was used to support efforts to control malaria.

Read full story · Comments are closed

Strengthening the Malaria Supply Chain in Niger

SIAPS Program provides support to the US President’s Malaria Initiative (PMI) country programs to address challenges to ensuring an uninterrupted supply of high-quality medicines and commodities as well as their appropriate use. SIAPS Program collaborates with PMI and field programs to strengthen pharmaceutical management systems for the benefit of national malaria control programs (NMCP). In Niger, SIAPS is supporting the NMCP to strengthen the systems for malaria commodities management.  This report summarizes activities carried out in Niger from October 1, 2015, to December 30, 2015.

Read full story · Comments are closed

PMI Coordinator Visits SIAPS-DRC

The Democratic Republic of the Congo (DRC), with one highest malaria incidence rates in the world, is a priority country for the President’s Malaria Initiative (PMI). PMI has played a major role in the country’s fight against malaria, having dedicated $50m toward eliminating the disease in DRC over the last five years. PMI Coordinator Rear […]

Read full story · Comments { 0 }

Malaria PMI Quarterly Updates April-June 2015

According to the World Health Organization (WHO), 1 malaria mortality rates fell by 47% globally, and by 54% in Africa between 2000 and 2013. During this period, an estimated 4.3 million malaria deaths were averted globally, primarily as a result of the scale-up of interventions. However, much remains to be done. Although 55 countries are on track to reduce their malaria case incidence rates by 75%, in line with the World Health Assembly and Roll Back Malaria (RBM) targets for 2015, these countries account for only 3% of all malaria cases.

Working closely with the President’s Malaria Initiative (PMI) in both Washington and PMI focus countries, the USAID-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program aims to ensure the availability of quality pharmaceutical products and effective pharmaceutical services in support of PMI objectives. To this end, and based on the PMI’s priorities, SIAPS endeavors to: improve pharmaceutical governance; build capacity to manage malaria products while addressing the information needed for managing them; strengthen financing strategies and mechanisms to improve access to malaria medicines; and improve the quality of pharmaceutical services provided to malaria patients.

Areas supported by SIAPS include: training; quantification; strengthening supply chain systems, including logistics management information; community and malaria case management; rational use; and medication safety. SIAPS works to strengthen malaria pharmaceutical management at the national level in Angola, Burundi, the Democratic Republic of the Congo (DRC), Ethiopia, Guinea, Mali, and South Sudan. In addition, SIAPS provides regional support in Latin America.

This report briefly describes the major activities that SIAPS conducted at the global level and in each of the countries and region mentioned above between April and June 2015.

Read full story · Comments are closed

Analysis of the Regulatory Capacity to Assure the Quality of Antimalarial Medicines in Selected Countries of the Greater Mekong Subregion of Asia

SIAPS conducted a review of regulatory and quality assurance efforts in the GMS with the following objectives—

  • To inform PMI of past and current initiatives to improve the capacity of the region to combat counterfeit, substandard, and banned antimalarial medicines
  • To understand the current barriers to effective medicine quality control for malaria
  • To recommend specific areas of focus or interventions to further improve regional and country capacity to combat counterfeit, substandard, and banned or illegal antimalarial medicines
Read full story · Comments are closed

Malaria PMI Quarterly Updates October-December 2014

According to the 2013 World Malaria Report,1 malaria incidence was reduced by about 31% and mortality rates by 49%in the World Health Organization (WHO) African Region between 2000 and 2012. These substantial reductions occurred as a result of a major scale-up of vector control interventions, diagnostic testing, and treatment with artemisinin-based combination therapies (ACTs). However, much remains to be done. The disease still took an estimated 627,000 lives in 2012,2 mostly children under five years of age in Africa.

Working closely with the President’s Malaria Initiative (PMI) both in Washington and in PMI focus countries, the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program aims to ensure the availability of quality pharmaceutical products and effective pharmaceutical services in support of PMI objectives. To this end, and based on PMI’s malaria program priorities, SIAPS endeavors to improve pharmaceutical governance, build capacity to manage malaria products while addressing the information needed for managing them, strengthen financing strategies and mechanisms to improve access to malaria medicines, and improve the quality of pharmaceutical services provided to malaria patients.

This report briefly describes the major activities that SIAPS conducted at the global level and in each of the above mentioned countries and regions between September and December 2014.

Read full story · Comments are closed

SIAPS/PMI – AMDM Scale-Up Sites Baseline Assessment

The President’s Malaria Initiative (PMI) is an interagency initiative led by the US Agency for International Development (USAID) with the US Centers for Disease Control and Prevention (CDC). PMI aims to reduce malaria-related mortality by 50% in 15 countries in sub-Saharan Africa by 2010. It plans to meet this goal by achieving 85% coverage of the most vulnerable groups—children under 5, pregnant women, and people living with HIV and AIDS—using proven preventive and therapeutic interventions, including artemisinin-based combination therapies (ACTs), insecticide-treated nets (ITNs), intermittent preventive treatment of malaria in pregnancy (IPTp), and indoor residual spraying (IRS).

Read full story · Comments are closed

Malaria PMI Quarterly Updates July–September 2014

According to the 2013 World Malaria Report, malaria incidence and mortality rates were reduced by about 31% and 49%, respectively, in the World Health Organization (WHO) African Region between 2000 and 2012. These substantial reductions occurred as a result of a major scale-up of vector control interventions, diagnostic testing, and treatment with artemisinin-based combination therapies (ACTs). However, much remains to be done. The disease still took an estimated 627,000 lives in 2012, mostly children under five years of age in Africa.

Working closely with the President’s Malaria Initiative (PMI) both in Washington and in PMI focus countries, the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program aims to ensure the availability of quality pharmaceutical products and effective pharmaceutical services in support of PMI objectives. To this end, and based on PMI’s malaria program priorities, SIAPS endeavors to improve pharmaceutical governance, build capacity to manage malaria products, strengthen information management,   strengthen financing strategies and mechanisms to improve access to malaria medicines, and improve the quality of pharmaceutical services provided to malaria patients.

The SIAPS technical approach emphasizes health systems strengthening with a special focus on improving metrics, monitoring and evaluation (M&E), developing the capacity of local governments and organizations, and increasing country ownership. Through this approach, SIAPS aims to promote the availability and use of malaria products, including ACTs, rapid diagnostic tests (RDTs), and medicines for severe malaria.

This report briefly describes the major activities that SIAPS conducted at the global level and in each of the above mentioned countries and regions between July and September 2014.

Read full story · Comments are closed

Malaria Quarterly Updates January–March 2014

This report briefly describes the major activities that SIAPS conducted at the global level and in Angola, Burundi, the Democratic Republic of the Congo (DRC), Ethiopia, Guinea, Mali, and South Sudan between January and March 2014.

Read full story · Comments are closed

Malaria Quarterly Updates October-December 2013

This report briefly describes the major activities that SIAPS carried out at the global level and in Angola, Burundi, the Democratic Republic of the Congo (DRC), Ethiopia, Guinea, Mali, and South Sudan between October and December 2013.

 

Read full story · Comments are closed